Assessment of Prolonged Administration of SynriamTM on Haematological Parameters and Lipid Profiles of Rats

Abstract

A potential antimalarial prospect should have high efficacy with low toxicity. SynriamTM antimalarial drug has been proven to be safe and effective for the treatment of malaria in human with dearth information on rats. This study investigated its potential toxicity from prolonged administration on lipid profiles and haematological indices in rats. Thirty-five Wistar rats were randomized into five groups (A – E) of seven rats each. Animals in group A (control) received 0.5 mL distilled water, while groups B, C, D, and E respectively received 4.0, 8.0, 16.0 and 32.0 mg/kg bwt of the drug once daily for 28 days. The concentrations of serum TC, LDL and atherogenic index showed significant (p<0.05) decrease, while serum TRIG, HDL, and VLDL concentrations had no effect (p>0.05). The drug also had no effect (p>0.05) on the levels of the red blood cell count, PCV, Hb, MCV, MCH, and MCHC. Similarly, it had no effect (p>0.05) on the levels of the WBC, lymphocytes and neutrocytes, while the platelet counts had slight (p<0.05) decrease. Hence, SynriamTM is relatively safe at doses of 4.0-32.0 mg/kg bwt in rats when taken once daily with minimal effects on the lipid profiles and haematological indices.